AR105050A1 - Procesos para preparar compuestos antivirales - Google Patents

Procesos para preparar compuestos antivirales

Info

Publication number
AR105050A1
AR105050A1 ARP150101834A ARP150101834A AR105050A1 AR 105050 A1 AR105050 A1 AR 105050A1 AR P150101834 A ARP150101834 A AR P150101834A AR P150101834 A ARP150101834 A AR P150101834A AR 105050 A1 AR105050 A1 AR 105050A1
Authority
AR
Argentina
Prior art keywords
compound
formula
stereoisomers
under conditions
conditions sufficient
Prior art date
Application number
ARP150101834A
Other languages
English (en)
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of AR105050A1 publication Critical patent/AR105050A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Abstract

Reivindicación 1: Un método para preparar un compuesto de la fórmula (1), o una de sus sales o solvatos, que comprende las etapas de: (a) puesta en contacto de un compuesto de la fórmula (2) o uno de sus estereoisómeros o mezclas de estereoisómeros, con un compuesto de la fórmula (3) o una de sus sales, en condiciones suficientes para obtener un compuesto de la fórmula (4), o uno de sus estereoisómeros o mezclas de estereoisómeros; (b) puesta en contacto del compuesto de la fórmula (4) con un compuesto de la fórmula (5) o una de sus sales, en condiciones suficientes para obtener un compuesto de la fórmula (6), o uno de sus estereoisómeros o mezclas de estereoisómeros; (c) ciclación de un compuesto de la fórmula (6) en condiciones suficientes para obtener un compuesto de la fórmula (7); (d) deshidrogenación del compuesto de la fórmula (7) en condiciones suficientes para obtener un compuesto de la fórmula (8); (e) desprotección del compuesto de la fórmula (8) en condiciones suficientes para obtener un compuesto de la fórmula (9) o una de sus sales; y (f) puesta en contacto del compuesto de la fórmula (9) con un compuesto de la fórmula (10), en condiciones suficientes para obtener un compuesto de la fórmula (1) o uno de sus estereoisómeros o mezcla de estereoisómeros, en donde PG es un grupo protector de amina, X e Y se seleccionan cada uno, de modo independiente, del grupo que consiste en halo, -OSO₂R, -OP(O)OR y -OP(O)(OR)₂, en donde R es alquilo, haloalquilo, arilo o arilo sustituido.
ARP150101834A 2014-06-11 2015-06-10 Procesos para preparar compuestos antivirales AR105050A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462010813P 2014-06-11 2014-06-11

Publications (1)

Publication Number Publication Date
AR105050A1 true AR105050A1 (es) 2017-09-06

Family

ID=53783899

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101834A AR105050A1 (es) 2014-06-11 2015-06-10 Procesos para preparar compuestos antivirales

Country Status (18)

Country Link
US (5) US9670187B2 (es)
EP (1) EP3154984B1 (es)
JP (4) JP6295348B2 (es)
KR (2) KR20180114253A (es)
CN (1) CN106488920A (es)
AR (1) AR105050A1 (es)
AU (3) AU2015274967B2 (es)
BR (1) BR112016028773B1 (es)
CA (1) CA2951138C (es)
EA (1) EA201692219A1 (es)
ES (1) ES2690868T3 (es)
IL (1) IL248960A0 (es)
MX (1) MX2016016297A (es)
NZ (1) NZ726356A (es)
PT (1) PT3154984T (es)
SG (1) SG11201609828SA (es)
TW (2) TWI679203B (es)
WO (1) WO2015191437A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2345661A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
AU2011328980B2 (en) 2010-11-17 2015-07-30 Gilead Pharmasset Llc Antiviral compounds
PL2635588T3 (pl) 2011-11-16 2015-10-30 Gilead Pharmasset Llc Skondensowane imidazoliloimidazole jako związki antywirusowe
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
TWI679203B (zh) 2014-06-11 2019-12-11 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
US10487067B2 (en) * 2015-10-08 2019-11-26 Mylan Laboratories Limited Process for the preparation of velpatasvir
US20190002480A1 (en) * 2015-12-21 2019-01-03 Merck Sharp & Dohme Corp. Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases
CN105712969B (zh) * 2016-01-27 2018-07-27 杭州科巢生物科技有限公司 维帕他韦中间体的合成方法
CN105732765B (zh) * 2016-02-01 2019-07-26 杭州科巢生物科技有限公司 丙肝药物维帕他韦的新合成方法
CN105732563B (zh) * 2016-03-23 2018-08-28 江苏苏利精细化工股份有限公司 一种合成9-溴-3-(2-溴乙酰基)-10，11-二氢-5H-二苯并[c,g]色烯-8(9h)-酮的新方法
EP3452038B1 (en) * 2016-05-05 2022-07-06 Laurus Labs Limited Process for the preparation of intermediates useful in the preparation of hepatitis c virus (hcv) inhibitors
WO2017195894A1 (ja) * 2016-05-13 2017-11-16 日産化学工業株式会社 ２－アセチルピリジン化合物の製造方法
CN106220639A (zh) * 2016-07-22 2016-12-14 上海众强药业有限公司 一种维帕他韦中间体新晶型
CN107573355B (zh) * 2016-11-30 2020-03-17 上海博志研新药物技术有限公司 维帕他韦、其中间体及制备方法
CN106831737B (zh) * 2017-02-27 2020-03-17 上海众强药业有限公司 维帕他韦及其衍生物的制备
CN107629029A (zh) * 2017-09-19 2018-01-26 安徽省诚联医药科技有限公司 维帕他韦中间体的制备方法
CN107501229A (zh) * 2017-09-27 2017-12-22 上海泓博智源医药股份有限公司 一种维帕他韦中间体的制备方法
CN107987125A (zh) * 2017-11-23 2018-05-04 爱斯特（成都）生物制药股份有限公司 一种缬氨酸衍生物的制备方法
CN108218755A (zh) * 2018-01-18 2018-06-29 上海仁实医药科技有限公司 一种N-Boc-4-氧代-L-脯氨酸叔丁酯的合成工艺
CN110835353B (zh) * 2018-08-15 2022-08-19 上海茂晟康慧科技有限公司 一种艾日布林中间体er804698的合成方法
CN109265431B (zh) * 2018-10-09 2020-05-26 江苏苏利精细化工股份有限公司 3-乙酰基-10，11-二氢-5h-二苯并[c,g]色烯-8（9h）-酮合成工艺
CN111018870B (zh) * 2019-11-29 2021-07-23 南京正济医药研究有限公司 一种维帕他韦中间体的制备方法
CN112275146B (zh) * 2020-09-01 2021-08-20 中国科学院山西煤炭化学研究所 一种经磷酸处理的Tröger`s Base聚合物气体分离膜及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8344155B2 (en) * 2009-09-04 2013-01-01 Glaxosmith Kline Llc Chemical compounds
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20120276047A1 (en) * 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
AU2011328980B2 (en) 2010-11-17 2015-07-30 Gilead Pharmasset Llc Antiviral compounds
PL2635588T3 (pl) 2011-11-16 2015-10-30 Gilead Pharmasset Llc Skondensowane imidazoliloimidazole jako związki antywirusowe
SG11201404754TA (en) * 2012-02-13 2014-09-26 Presidio Pharmaceuticals Inc Solid forms comprising inhibitors of hcv ns5a, compositions thereof, and uses therewith
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9056860B2 (en) * 2012-06-05 2015-06-16 Gilead Pharmasset Llc Synthesis of antiviral compound
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
TWI679203B (zh) 2014-06-11 2019-12-11 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式

Also Published As

Publication number Publication date
PT3154984T (pt) 2018-11-07
BR112016028773B1 (pt) 2023-02-07
KR20180114253A (ko) 2018-10-17
CA2951138A1 (en) 2015-12-17
TW202014413A (zh) 2020-04-16
TW201609744A (zh) 2016-03-16
US9670187B2 (en) 2017-06-06
US11192875B2 (en) 2021-12-07
KR101908642B1 (ko) 2018-10-17
JP2017517541A (ja) 2017-06-29
CN106488920A (zh) 2017-03-08
US20150361073A1 (en) 2015-12-17
WO2015191437A1 (en) 2015-12-17
US9890134B2 (en) 2018-02-13
JP6295348B2 (ja) 2018-03-14
BR112016028773A2 (pt) 2017-08-22
US10584109B2 (en) 2020-03-10
JP2019178179A (ja) 2019-10-17
AU2015274967A1 (en) 2016-12-01
AU2018204886B2 (en) 2020-08-06
AU2015274967B2 (en) 2018-04-05
EA201692219A1 (ru) 2017-05-31
US20190263771A1 (en) 2019-08-29
MX2016016297A (es) 2017-05-01
US20200392100A1 (en) 2020-12-17
AU2020264335A1 (en) 2020-11-26
ES2690868T3 (es) 2018-11-22
KR20170015493A (ko) 2017-02-08
SG11201609828SA (en) 2016-12-29
CA2951138C (en) 2019-12-24
NZ726356A (en) 2018-06-29
JP6954959B2 (ja) 2021-10-27
AU2018204886A1 (en) 2018-07-26
IL248960A0 (en) 2017-01-31
US20180179175A1 (en) 2018-06-28
US20170283390A1 (en) 2017-10-05
EP3154984A1 (en) 2017-04-19
JP2018052985A (ja) 2018-04-05
JP2021178872A (ja) 2021-11-18
TWI679203B (zh) 2019-12-11
AU2020264335B2 (en) 2022-10-27
EP3154984B1 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
AR105050A1 (es) Procesos para preparar compuestos antivirales
CO2017012403A2 (es) Proceso para preparar 4-amino-piridazinas
SV2017005587A (es) Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceutacas que los contienen
UY36999A (es) Derivados de aryl oxadiazol fungicidas
SV2018005722A (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
CL2018003504A1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos.
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CO2018013141A2 (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que los contienen
UY37062A (es) Derivados de aryl oxadiazol fungicidas
CL2018003474A1 (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen.
UY36733A (es) Nuevos derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
CO2017000337A2 (es) Derivados de bis(aril)catecol como herbicidas
UY36122A (es) ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1?
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
CO2018005954A2 (es) Compuestos heteroaromáticos como inhibidores de btk
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
CO2019007834A2 (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
CL2017002745A1 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
CO2018004213A2 (es) Compuesto piranodipiridínico
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
CL2019000050A1 (es) Procesos para la preparacion de oxipicolinamidas 4 - alkoxi - (acil o aquil).
EA201790408A1 (ru) Зонды для визуализации белка хантингтина
DOP2016000211A (es) Pirazinas moduladoras de gpr6
BR112017009854A2 (pt) composto, uso de um composto, e, método para tratamento de leucemia.

Legal Events

Date Code Title Description
FB Suspension of granting procedure